

Date: 6th February, 2024

To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrin Code: 533573 To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023, published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 6th February, 2024.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf Company Secretary

Encl.: A/a.

WWW.INDIANEXPRESS.COM THE INDIAN EXPRESS. TUESDAY, FEBRUARY 6, 2024



ALEMBIC PHARMACEUTICALS LI Can L342003.000 0FLC001/03-Pagel Office: Abestic Road, Modelars - 000 Ser - 0005-8617/00

Tei 000-6637008 Email spl. Invadors@alenticcoo.in Mhibester laxue alenticg/remocraticals.com

If in Crones except per share o				
Particulars	Quarter Ended		Year Ended	
	21.12.2023	21.12.2022	31,83,2822	
The second second second second	(Unaudited)	(Unaucited)	(And ted)	
Total Income from Operations	1,630.57	1,508.02	5,852.82	
Net Profit for the period (before Tax, Exceptional and/or Exceptionary thems)	184.58	154.48	354.59	
Net Profit for the period before to: Jeffer Exceptional and/ or Extraordinary (terns)	184.58	154.48	354.50	
hist Profit for the period after tax abstractable to shareholders of the company (after Exceptional and/ or Exceptionary Items)	132.45	12132	341.99	
Total Comprehensive Income for the period	151.49	124.34	355.36	
Equity Share Capital	38.21	39.31	36.31	
Earring Per Share (Face Value of 7 27- each) Basic & Oiluted	1.56	6.20	17.40	
Farsearch and Development Expenses	114.48	156.89	721.84	
Notes:	100			

	31.12.2023	\$1.12.2022	31.63.2623
	(Unaudited)	disadted	Outres
Income thora Operations	1,568.39	1,010,21	5,149.00
Froit Before Tax	218.70	144.31	345.53
Fronte Affeit Tax	233.24	119.13	346.73
Fassarch and Development Expenses	113.76	149.02	699.29

www.dendophamicente

0.000

Chiraya Amia Chalaman and CES

ફાયનાન્સિયલ એક્સપ્રેસ

*	Alembic	City L343306. Ragd Officer of the 0255-6507 Email: any low	PHARMACEUTII 02110PL0061129 Nanbis Foad, Vadoo 300 shara@oonbis ss in skanbispharmsousis	ma - 380 003
	Extract of Statement of Con the quarter and nine ma	rsolidated Unau oths period end	ed 31 Decemb	er, 2023
-	1000101010101010101010101010101010101010			api per share da
	Particulars		r Ended	Year Ended
	- THE COMP	31,12,2923 (((audited)	31.12.2022 0.jnapdited	31.83.2923 (Audited)
	I Income from Operations	5,680,67	1,589.02	5,652.62
De	Profit for the period one Tox, Exceptional and or acodinary Remej	184.58	154.49	354.59
H	Profit for the period before too or Ecoptional and/ or acedinary items;	184,68	154.46	354.59
Mr.	Profit for the period after tax butable to shawheaders of the spany (after Exceptional and or acedinary items)	180.45	121.92	341.99
	I Comprehensive income for peried	181.40	120.94	355.36
te	by Share Capital	29.21	39.31	38.31
Ear T S	ring Per Share (Face Value of rook) Sooic & Dilated	9.13	6.26	17.60
See.	worth and Development Expenses	154,48	156.88	721.84
Ny.	16:	AND RESIDENCE OF THE PARTY OF T	THE RESERVE OF THE PERSON NAMED IN	ALL YES
1,	Standalone details	Coorter		Year Ended
	THE RESERVE	31.12.2023	31 12 2002	31,03,2022
		(Ussed ted)	(Unaudited)	(Audited)
	Income from Operations	1,588.29	1,310.21	5,148,00
	Profit Below Tax	254.70	144.31	345.83
	Proff.After Tex	233.24	119.13	345.73
	Research and Development. Expenses	113.78	149.32	608.30
2	The above is an extract of the cletal Stock Exchanges. The detailed File years all or the common control of the cletal common control of the common control of the cletal common control of the cletal common control of the cletal common control of the cletal control of control of the cletal control of the cletal control of the cletal control of control of co	BYCSE PROJEK MY R	remain on the Con	DRY'S MESSE

Date : 5° February, 2004

Chairman a



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2810PLC061123

Regd. Office: Alembic Road, Vadedara - 390 003

Tel: 0265-6837300

Email: apl. investors@alembic.co.in

Website: www.alembicpharmagsuficals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023

the quarter and nine months period ended 31 December, 2020			
(₹ in Crores except per share data)			
Particulars	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	1,630.57	1,509.02	5,652.62
Net Profit for the period	184.58	154.49	354.59
(before Tax, Exceptional and/ or Extraordinary items)		(deugle)	16 BUS/A
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	184.58	154.49	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	180.45	121.92	341.99
Total Comprehensive Income for the period	181.49	124.94	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.18	6.20	17.40
Research and Development Expenses	114.48	156.89	721.84

1.

1. Standalone	Standalone details			
	Stalluaione uctura	31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Audited)
	Income from Operations	1,588.39	1,310.21	5,149.00
	Profit Before Tax	256.70	144.31	345.93
	Profit After Tax	233.24	119.13	346.73
	Besearch and Development	113.75	149.02	699.39

Expenses

The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.selmbiopharmacouticals.com and the Stock Exchange's website at www.nseindia.com and www.beindia.com.

For Alembic Pharmaceuticals Limited

Place : Vadodara Date : 5" February, 2024 Chirayu Amin Chairman and CEO